BSA-NBD-Palmitate Saturated Fatty Acid Complex (1 mM)

BSA-NBD-Palmitate Saturated Fatty Acid Complex (1 mM) is composed of NBD-palmitic acid (Item No. 44455) and fatty acid-free bovine serum albumin (BSA) at an approximately 6:1 molar ratio of NBD-palmitate:BSA. It displays excitation/emission maxima of 467/550 nm, respectively, and can be used to visualize lipid uptake using fluorescence microscopy or flow cytometry to study the effect of long-chain fatty acids on gene and protein expression, lipid droplet formation, hepatocyte lipid accumulation, and oxidative stress.^1,2,3 Cayman’s BSA-NBD-Palmitate Saturated Fatty Acid Complex (1 mM) is suitable for use in short-term cell culture applications (acute treatment to 18 hours); however, for long-term applications (25+ hours) the product should be filter-sterilized using a 0.2 µm filter and sterile receptacle, which will not affect its performance. For best results, it is recommended that this product be used in conjunction with Cayman's BSA Control for BSA-Fatty Acid Complexes (1 mM) (Item No. 34932), prepared with fatty acid-free BSA.

WARNING This product is not for human or veterinary use.

1. Muthusamy, G., Liu, C.-C., and Johnston, A.N. Deletion of PGAM5 downregulates FABP1 and attenuates long-chain fatty acid uptake in hepatocellular carcinoma. Cancers (Basel) 15(19), 4796 (2023).

2. Das, S., Finney, A.C., Anand, S.K., et al. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis. Nat. Metab. 6(10), 1939-1962 (2024).

3. Guilfoyle-Speese, A., Patel, K., Ghanwat, A.H., et al. Short-chain fatty acids and palmitate induce distinct metabolic and phenotypic signatures in normal and ischemic skeletal muscle microvascular endothelial cells. Cells 15(6), 493 (2026).